Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines

Prostate

Volumn 60, Issue 2, 2004, Pages 98-108

  Liu, Alvin Y ^a,b   Brubaker, Kristen D ^a   Goo, Young Ah ^b   Quinn, Janna E ^a   Kral, Sabine ^a   Sorensen, Carrie M ^b   Vessella, Robert L ^a   Belldegrun, Arie S ^c   Hood, Leroy E ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

C4 2; CD26; CL1; LNCaP subpopulations

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; HERMES ANTIGEN; MICROSOMAL AMINOPEPTIDASE;

ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CELL LINEAGE; CELL SELECTION; CELL STRAIN C4 2; CELL STRAIN CL1; CELL STRAIN LNCAP; CELL SUBPOPULATION; DNA MICROARRAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIGENS, CD; CELL DIFFERENTIATION; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 2942561949     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20031     Document Type: Article

References (35)

1. Horoszewicz JS, Leong SS, Kawinski E, Karr J, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of a human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
2. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002;99:11890-11895.
3. Zhau HE, Chung LWK. Establishment of human prostate carcinoma skeletal metastasis models. Cancer 2000;88:2995-3001.
4. Wu H, Hsieh J, Gleave ME, Brown NM, Pathak S, Chung LWK. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 1994;57:406-412.
5. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang S, Ozen M, Pathak S, Chung LWK. LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate 2000;44:91-103.
6. Koeneman KS, Yeung F, Chung LWK. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-261.
7. Lin D, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001;47:212-221.
8. Tso C, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J Sci Am 2000;6:220-233.
9. Patel BJ, Pantuck AJ, Zisman A, Tsui KH, Paik SH, Caliliw R, Sheriff S, Wu L, deKernion JB, Tso C, Belldegrun AS. CL1-GFP: An androgen independent metastatic tumor model for prostate cancer. J Urol 2000;164:1420-1425.
10. Liu AY. Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 2000;60:3429-3434.
11. Liu AY, True LD. Characterization of prostate cell types by CD cell surface molecules. Am J Pathol 2002;160:37-43.
12. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso C, Palotie AV, Belldegrun AS. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003;55:71-80.
13. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, Lange PH, Hood L, van den Engh G. Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci USA 1997;94:10705-10710.
14. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL. LuCaP 35: A new model of prostate cancer progression to androgen independence. Prostate 2003;55:239-246.
15. Ewing B, Green P. Analysis of expressed sequence tags indicates 35,000 human genes. Nat Genet 2000;25:232-234.
16. Ideker TE, Thorsson V, Siegel AP, Hood LE. Testing for differentially expressed genes by maximum-likelihood analysis of microarray data. J Comput Biol 2000;7:805-817.
17. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998;4:50-57.
18. Dinjens WN, ten Kate J, van der Linden EP, Wijnen JT, Meera Khan P, Bosman FT. Distribution of adenosine deaminase complexing protein (ADCP) in human tissues. J Histochem Cytochem 1989;37:1869-1875.
19. Dinjens WN, ten Kate J, Kirch JA, Tanke HJ, van der Linden EP, van den Ingh HF, van Steenbrugge GJ, Meera Khan P, Bosman FT. Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas. J Pathol 1990;160:195-201.
20. Vanhoof G, DeMeester I, van Sande M, Scharpe S, Yaron A. Distribution of proline-specific aminopeptidase in human tissues and body fluids. Eur J Clin Chem Clin Biochem 1992;30:333-338.
21. Ghersi G, Dong H, Goldstein LA, Yeh Y, Hakkinen L, Larjava HS, Chen WT. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem 2002;277:29231-29241.
22. Johnson RC, Zhu D, Augustin-Voss HG, Pauli BU. Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung metastatic rat breast and prostate carcinoma cells. J Cell Biol 1993;121:1423-1432.
23. Abdel-Ghany M, Cheng H, Levine RA, Pauli BU. Truncated dipeptidyl peptidase IV is a potent anti-adhesion and antimetastasis peptide for rat breast cancer cells. Invasion Metastasis 1998;18:35-43.
24. Gonzalez-Gronow M, Grenett HE, Weber MR, Gawdi G, Pizzo SV. Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. Biochem J 2001;355:397-407.
25. Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncologia 2002;41:289-296.
26. Hirai K, Kotani T, Aratake Y, Ohtaki S, Kuma K. Dipeptidyl peptidase IV (DPPIV/CD26) staining predicts distant metastasis of 'benign' thyroid tumor. Pathol Int 1999;49:264-265.
27. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 2002;52:20-33.
28. Corey E, Quinn JE, Vessella RL. A novel method of generating prostate cancer metastases from orthotopic implants. Prostate 2003;56:110-114.
29. Wang X, An Z, Geller J, Hoffman RM. High-malignancy orthotopic nude mouse model of human prostate cancer LNCaP. Prostate 1999;39:182-186.
30. Yao T, Takata M, Tustsumi S, Nishiyama K, Taguchi K, Nagai E, Tsuneyoshi M. Phenotypic expression of gastrointestinal differentiation markers in colorectal adenocarcinomas with liver metastasis. Pathology 2002;34:556-560.
31. Kanitakis J, Narvaez D, Claudy A. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res 2002;12:241-244.
32. Saiki I, Fujii H, Yoneda J, Abe F, Nakajima M, Tsuruo T, Azuma I. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 1993;54:137-143.
33. Tokuhara T, Adachi M, Hashida H, Ishida H, Taki T, Higashiyama M, Kodama K, Tachibana S, Sasaki S, Miyake M. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 2001;49:489-496.
34. Hass GM, Meyer JL, Newitt RA, Labuda T, Brown L, Aebersold R, Vessella RL. Identification of the target of monoclonal antibody A6H as dipeptidyl peptidase IV/CD26 by LC MSMS Hybridoma 2001;20:231-236.
35. Tan PH, Chu V, Stray JE, Hamlin DK, Pettit D, Wilbur DS, Vessella RL, Stayton PS. Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. Immunotechnology 1998;4:107-114.